BiondVax - Chart Of The Day - Top 100 Stock
Summary
- 100% technical buy signals.
- 13 new highs and up 102.55% in the last month.
- 596.92% gain in the last year.
The Barchart Chart of the Day belongs to the Biopharmaceutical company BiondVax Pharmaceutical (BVXV). I found the stock by sorting Barchart's Top 100 Stock list first by the most frequent number of new highs in the last month, then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy in 4/17 the stock gained 358.89%.
BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company. The company's product includes Multimeric-001 universal flu vaccine which provides multi-season and multi-strain protection against human influenza virus strains. BiondVax Pharmaceuticals Ltd. is based in Ness Ziona, Israel.
Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.
Barchart technical indicators:
- 100% technical buy signals
- 326.10+ Weighted Alpha
- 596.92% gain in the last year
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 13 new highs and up 102.55% in the last month
- Relative Strength Index 84.55%
- Technical support level at 34.08%
- Recently traded at 41.51 with a 50 day moving average of 21.17
Fundamental factors:
- Market Cap $443 million
- The Wall Street analysts following the stock hasn't made Revenue and Earnings estimates available but has given the stock a Buy recommendation
- The individual investors following the stock on Motley Fool voted 5 to 1 that the stock will beat the market
- 1,170 investors are monitoring the stock on Seeking Alpha
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.